Skip to main content

Advertisement

Table 1 Model parameters

From: Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab

  Panitumumab Cetuximab Range tested for sensitivity analysis References
Survival outcomes (months)
 Median PFS 4.1 4.4 95% CI [7]
 Median OS 10.4 10 95% CI [7]
Cost
 Drug acquisition $4224a $1113b ± 20% [10]
 Chemotherapy administration $272 $330 ± 20% [12]
 AEs management (per event)    ± 20%  
  Skin rash $5484   [13]
  Hypomagnesemia $7654   [13]
  Hypokalemia $1605   [15]
  Infusion reaction $2138 (Grade 1 and 2)   [14]
  $12,197 (≥ Grade 3)   
 Caregiver costs (per month)    ± 20%  
  Progression-free $1462   [17]
  Progression $2521   [17]
 Best supportive care (per month) $2754 ± 20% [16]
Utility
 Progression-free state 0.745 0.74 ± 20% [18, 19]
 Progressive state 0.65 0.65 ± 20% [20]
  1. PFS progression-free survival, OS overall survival, BSC best supportive care
  2. aDrug acquisition cost for panitumumab of 400 mg/20 ml vial
  3. bDrug acquisition cost for cetuximab of 100 ml 2 mg/ml vial